Literature DB >> 19467614

Growth hormone isoforms.

Gerhard P Baumann1.   

Abstract

Human growth hormone (GH) is a heterogeneous protein hormone consisting of several isoforms. The sources of this heterogeneity reside at the level of the genome, mRNA splicing, post-translational modification and metabolism. The GH gene cluster on chromosome 17q contains 2 GH genes (GH1 or GH-N and GH2 or GH-V) in addition to 2(-3) genes encoding the related chorionic somatomammotropin. Alternative mRNA splicing of the GH1 transcript yields two products: 22K-GH (the principal pituitary GH form) and 20K-GH. Post-translationally modified GH forms include N(alpha)-acylated, deamidated and glycosylated monomeric GH forms, as well as both non-covalent and disulfide-linked oligomers up to at least pentameric GH. GH fragments generated in the course of peripheral metabolism may be measured in immunoassays for GH. The GH-N gene is expressed in the pituitary, the GH-V gene in the placenta. Secretion of pituitary GH forms is pulsatile under control from the hypothalamus, whereas secretion of placental GH-V is tonic and rises progressively in maternal blood during the 2nd and 3rd trimester. Pituitary GH forms are co-secreted during a secretory pulse; no isoform-specific stimuli have been identified. There are minor differences in somatogenic and metabolic bioactivity among the GH isoforms, depending on species and assay system used. Both 20K-GH and GH-V have poor lactogenic activity. Oligomeric GH forms have variably diminished bioactivity compared to monomeric forms. GH isoforms cross-react in most immunoassays, but assays specific for 22K-GH, 20K-GH and GH-V have been developed. The metabolic clearance of 20K-GH and GH oligomers is delayed compared to that of 22K-GH. The heterogeneous mixture of GH isoforms in blood is further complicated by the presence of two GH-binding proteins, which form complexes with GH; isoform proportions also vary depending on the lag time from a secretory pulse because of different half-lives. GH forms excreted in the urine reflect monomeric GH isoforms in blood, but constitute only a minute fraction of the GH production rate. The heterogeneity of GH is one important reason for the notorious disparity among assay results. It also presents an opportunity for distinguishing endogenous from exogenous GH.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19467614     DOI: 10.1016/j.ghir.2009.04.011

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  22 in total

1.  Novel serum protein biomarkers indicative of growth hormone doping in healthy human subjects.

Authors:  Juan Ding; Shigeru Okada; Jens Otto Lunde Jørgensen; John J Kopchick
Journal:  Proteomics       Date:  2011-07-27       Impact factor: 3.984

2.  Exploiting Nanobodies in the Detection and Quantification of Human Growth Hormone via Phage-Sandwich Enzyme-Linked Immunosorbent Assay.

Authors:  Hossam Murad; Jana Mir Assaad; Rasha Al-Shemali; Abdul Qader Abbady
Journal:  Front Endocrinol (Lausanne)       Date:  2017-05-30       Impact factor: 5.555

3.  Human growth hormone: 45-kDa isoform with extraordinarily stable interchain disulfide links has attenuated receptor-binding and cell-proliferative activities.

Authors:  Juan J Bustamante; Alexei L Grigorian; Jesus Muñoz; Roberto M Aguilar; Lisa R Treviño; Andrew O Martinez; Luis S Haro
Journal:  Growth Horm IGF Res       Date:  2010-05-15       Impact factor: 2.372

4.  Growth hormone and proopiomelanocortin are targeted by autoantibodies in a patient with biopsy-proven IgG4-related hypophysitis.

Authors:  M A Landek-Salgado; P Leporati; I Lupi; A Geis; P Caturegli
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

Review 5.  Biochemical investigations in diagnosis and follow up of acromegaly.

Authors:  Katharina Schilbach; Christian J Strasburger; Martin Bidlingmaier
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

6.  Discovery of prolactin-like in lamprey: Role in osmoregulation and new insight into the evolution of the growth hormone/prolactin family.

Authors:  Ningping Gong; Diogo Ferreira-Martins; Jessica L Norstog; Stephen D McCormick; Mark A Sheridan
Journal:  Proc Natl Acad Sci U S A       Date:  2022-09-26       Impact factor: 12.779

Review 7.  Growth hormone - past, present and future.

Authors:  Michael B Ranke; Jan M Wit
Journal:  Nat Rev Endocrinol       Date:  2018-03-16       Impact factor: 43.330

Review 8.  Obesity, growth hormone and exercise.

Authors:  Gwendolyn A Thomas; William J Kraemer; Brett A Comstock; Courtenay Dunn-Lewis; Carl M Maresh; Jeff S Volek
Journal:  Sports Med       Date:  2013-09       Impact factor: 11.136

9.  Somatotropin in the treatment of growth hormone deficiency and Turner syndrome in pediatric patients: a review.

Authors:  Christina Southern Reh; Mitchell E Geffner
Journal:  Clin Pharmacol       Date:  2010-06-01

10.  The intricate role of growth hormone in metabolism.

Authors:  Archana Vijayakumar; Shoshana Yakar; Derek Leroith
Journal:  Front Endocrinol (Lausanne)       Date:  2011-09-27       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.